PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 176-200 of 369

  • PI3K/AKT-IN-2
    Cat. No.
    A25824

    PI3K/AKT-IN-2

    PI3K/AKT-IN-2 is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways. This compound effectively prevents epithelial-mesenchymal transition (EMT) and promotes apoptosis in various cancer cell lines. Additionally, PI3K/AKT-IN-2 has been shown to inhibit tubulin polymerization, making it a valuable tool for research into cancer metastasis and cell proliferation.

    5 mg
    $160.00
    10 mg
    $265.00
    All 5 sizes
  • TASP0415914
    Cat. No.
    A25840

    TASP0415914

    TASP0415914 is a potent and orally active inhibitor of PI3Kγ, exhibiting an IC50 of 29 nM. In addition, it demonstrates significant inhibitory activity against Akt with an IC50 of 294 nM. This compound is applicable in research focused on inflammatory diseases and may provide insights into the modulation of signaling pathways involved in inflammation.

    1 mg
    $40.00
    5 mg
    $100.00
    All 7 sizes
  • IBL-302
    Cat. No.
    A25844

    IBL-302

    Synonyms: AMU302

    IBL-302 is an orally available dual inhibitor targeting PIM and the PI3K/AKT/mTOR pathways. It exhibits significant antitumor activity against breast cancer and neuroblastoma, showing in vivo efficacy in nude mouse xenograft models by overcoming trastuzumab resistance. Additionally, IBL-302 enhances the cytotoxic effects of commonly used chemotherapeutic agents, including cisplatin, doxorubicin, and etoposide, making it a valuable compound for cancer research applications.

    1 mg
    $310.00
    5 mg
    $805.00
    All 4 sizes
  • 25(R,S)-Ruscogenin
    Cat. No.
    A25887

    25(R,S)-Ruscogenin

    25(R,S)-Ruscogenin is a potent inhibitor of the PI3K/Akt/mTOR and TLR4 signaling pathways. This compound effectively suppresses hepatocellular carcinoma (HCC) metastasis by decreasing the expression of matrix metalloproteinases (MMP-2 and MMP-9), uPA, VEGF, and HIF-1α. Additionally, 25(R,S)-Ruscogenin mitigates LPS-induced apoptosis in pulmonary endothelial cells, highlighting its potential for applications in cancer research and inflammatory disease studies.

    1 mg
    $35.00
    5 mg
    $80.00
    All 6 sizes
  • (E)-Akt inhibitor-IV
    Cat. No.
    A25910

    (E)-Akt inhibitor-IV

    Synonyms: (E)-AKTIV

    (E)-Akt inhibitor-IV is a potent PI3K-Akt inhibitor that selectively targets the Akt signaling pathway. It demonstrates significant cytotoxic activity against various cancer cell lines, making it a valuable tool for studying tumor biology and therapeutic resistance. Research applications include investigating the role of Akt in cell proliferation, survival, and apoptosis in cancer models.

    1 mg
    $40.00
    5 mg
    $95.00
    All 7 sizes
  • KTC1101
    Cat. No.
    A25946

    KTC1101

    KTC1101 is a potent oral pan-PI3K inhibitor targeting the phosphoinositide 3-kinase (PI3K) signaling pathway. It effectively reduces downstream phosphorylation of AKT and mTOR, leading to decreased expression of Ki67. KTC1101 exhibits dual anti-tumor mechanisms by directly inhibiting tumor cell proliferation and enhancing the immune response, making it a valuable tool for cancer research and therapeutic applications.

    1 mg
    $60.00
    5 mg
    $130.00
    All 6 sizes
  • AKT inhibitor IV
    Cat. No.
    A25953

    AKT inhibitor IV

    Synonyms: AKTIV

    AKT Inhibitor IV is a potent PI3K-Akt pathway inhibitor that selectively targets the E isomer. This compound exhibits significant cytotoxic effects, making it valuable for research applications focusing on cell proliferation, survival, and apoptosis. It is ideal for studies investigating the role of the PI3K-Akt signaling pathway in cancer and other diseases.

    1 mg
    $75.00
    All 1 sizes
  • Notoginsenoside Ft1
    Cat. No.
    A26006

    Notoginsenoside Ft1

    Notoginsenoside Ft1 is a potent PI3K/AKT/mTOR inhibitor with significant bioactive properties. This compound induces apoptosis and lysosomal cell death in various cancer cell types by modulating key signaling pathways, such as p38 MAPK and ERK1/2, while promoting angiogenesis. Additionally, Notoginsenoside Ft1 enhances CD8+ T cell populations and exerts vasodilatory effects through glucocorticoid and estrogen receptor beta activation in endothelial cells. By acting as a TGR5 agonist and FXR antagonist, it may provide protective effects against renal injury and contribute to the management of obesity and insulin resistance through the modulation of intracellular calcium and cAMP levels.

    5 mg
    $65.00
    10 mg
    $85.00
    All 2 sizes
  • PI3K/HDAC-IN-3
    Cat. No.
    A26375

    PI3K/HDAC-IN-3

    PI3K/HDAC-IN-3 is a dual inhibitor targeting PI3K and HDAC, with IC50 values of 0.23 nM for PI3Kα and 172 nM for HDAC1. It effectively suppresses AKT phosphorylation while enhancing H3 acetylation in MV4-11 cells. Additionally, PI3K/HDAC-IN-3 demonstrates notable anticancer efficacy in a dose-dependent manner within an MV4-11 xenograft model, making it a valuable tool for studying cancer biology and potential therapeutic interventions.

    Out of stock

    All 3 sizes
  • PI3Kα/HDAC6-IN-1
    Cat. No.
    A26377

    PI3Kα/HDAC6-IN-1

    PI3Kα/HDAC6-IN-1 is a dual inhibitor targeting PI3Kα and HDAC6, exhibiting IC50 values of 2.9 nM and 26 nM, respectively. This compound effectively inhibits AKT (Ser473) phosphorylation and promotes the accumulation of acetylated α-tubulin, while not influencing acetylated histones H3 and H4. Its potent anti-cancer activity is demonstrated in the L-363 cell line with an IC50 of 0.17 μM, highlighting its potential for therapeutic applications in cancer research.

    Out of stock

    All 3 sizes
  • PI3K/HDAC-IN-1
    Cat. No.
    A26472

    PI3K/HDAC-IN-1

    PI3K/HDAC-IN-1 is a potent dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC). It effectively inhibits PI3Kδ and HDAC1 with IC50 values of 8.1 nM and 1.4 nM, respectively. This compound is valuable for studying the roles of PI3K and HDAC in various cellular processes and can aid in cancer research by exploring the therapeutic potential of dual inhibition in tumor models.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • PI3K/HDAC-IN-2
    Cat. No.
    A26517

    PI3K/HDAC-IN-2

    PI3K/HDAC-IN-2 is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), demonstrating IC50 values of 226 nM for PI3Kα, 279 nM for PI3Kβ, 467 nM for PI3Kγ, and 29 nM for PI3Kδ. It also exhibits selective inhibition with IC50 values of 1.3 nM for HDAC1, 3.4 nM for HDAC2, 972 nM for HDAC4, 17 nM for HDAC6, and 12 nM for HDAC8. Due to its significant anticancer properties, PI3K/HDAC-IN-2 is valuable for research applications in cancer biology and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Copanlisib dihydrochloride
    Cat. No.
    A30054

    Copanlisib dihydrochloride

    Synonyms: BAY 80-6946 dihydrochloride

    Copanlisib dihydrochloride is a potent, selective pan-class I PI3K inhibitor that acts through ATP-competitive mechanisms. It exhibits remarkable inhibitory activity with IC50 values of 0.5 nM, 0.7 nM, 3.7 nM, and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ, and PI3Kγ, respectively, demonstrating over 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. This compound has been shown to possess significant antitumor activity, making it a valuable reagent for cancer research and therapeutic development focusing on the PI3K pathway.

    5 mg
    $40.00
    10 mg
    $60.00
    All 5 sizes
  • BAY1082439
    Cat. No.
    A30429

    BAY1082439

    BAY1082439 is a selective inhibitor of the PI3Kα, β, and δ isoforms, demonstrating oral bioavailability. This compound effectively inhibits both wild-type and mutated forms of PIK3CA, making it a valuable tool in cancer research. Notably, BAY1082439 has shown significant efficacy in suppressing the growth of Pten-null prostate cancer, highlighting its potential in therapeutic applications targeting specific tumors.

    1 mg
    $25.00
    2 mg
    $35.00
    All 7 sizes
  • PI3Kα-IN-9
    Cat. No.
    A30642

    PI3Kα-IN-9

    PI3Kα-IN-9 is a selective inhibitor of PI3Kα, exhibiting an IC50 of 4.4 nM while demonstrating lesser potency against PI3Kγ, PI3Kδ, and PI3Kβ with IC50 values of 128, 146, and 153 nM, respectively. This compound is notable for its long-acting oral activity and ability to induce apoptosis alongside antiproliferative effects in cancer cells. PI3Kα-IN-9 serves as a valuable reagent for cancer research, particularly in studies focused on PI3K signaling pathways.

    1 mg
    $25.00
    5 mg
    $60.00
    All 6 sizes
  • FD223
    Cat. No.
    A30963

    FD223

    FD223 is a potent and selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), demonstrating an IC50 of 1 nM. It shows significant selectivity over other isoforms, with IC50 values of 51 nM, 29 nM, and 37 nM for α, β, and γ, respectively. FD223 effectively inhibits the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473, leading to G1 phase arrest in the cell cycle. This compound holds potential for research into leukemia, particularly AML.

    5 mg
    $170.00
    10 mg
    $285.00
    All 5 sizes
  • FD274
    Cat. No.
    A31127

    FD274

    FD274 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 0.65 nM for PI3Kα, 1.57 nM for PI3Kβ, 0.65 nM for PI3Kγ, 0.42 nM for PI3Kδ, and 2.03 nM for mTOR. This compound demonstrates significant anti-proliferative effects on acute myeloid leukemia (AML) cell lines, specifically HL-60 and MOLM-16, inducing G1 phase cell cycle arrest and promoting apoptosis. In vivo studies reveal dose-dependent inhibition of tumor growth in HL-60 xenograft models, making FD274 a valuable tool for research into acute myeloid leukemia therapies.

    1 mg
    $155.00
    5 mg
    $250.00
    All 7 sizes
  • PARP/PI3K-IN-1
    Cat. No.
    A31240

    PARP/PI3K-IN-1

    PARP/PI3K-IN-1 is a potent inhibitor of both PARP and PI3K, exhibiting pIC50 values of 8.22 for PARP-1, 8.44 for PARP-2, and varying activity against PI3K isoforms with values of 8.25 for PI3Kα, 6.54 for PI3Kβ, 8.13 for PI3Kδ, and 6.08 for PI3Kγ. This compound demonstrates significant anticancer activity and is suitable for research applications targeting a variety of oncological disorders. Its dual inhibition may provide insights into therapeutic strategies for cancer treatment.

    1 mg
    $80.00
    5 mg
    $210.00
    All 6 sizes
  • PI3Kδ-IN-16
    Cat. No.
    A31332

    PI3Kδ-IN-16

    PI3Kδ-IN-16 is a highly selective inhibitor of the PI3Kδ isoform, displaying an impressive IC50 value of 0.9 nM. This compound exhibits significant anti-proliferative effects on SU-DHL-6 cells, leading to cell cycle arrest and the induction of apoptosis. PI3Kδ-IN-16 demonstrates substantial selectivity for PI3Kδ over other isoforms, with a kinase activity that is approximately 378-fold greater than PI3Kα, 412-fold greater than PI3Kβ, and 10-fold greater than PI3Kγ. It is a valuable tool for research into hematologic malignancies and the therapeutic targeting of PI3Kδ.

    1 mg
    $75.00
    5 mg
    $185.00
    All 6 sizes
  • PWT-33597 free base
    Cat. No.
    A31509

    PWT-33597 free base

    Synonyms: VDC-597 free base

    PWT-33597 free base is a dual inhibitor targeting PI3Kα and mTOR, effectively disrupting downstream signaling pathways associated with cell growth and metabolism. This compound induces apoptosis in tumor cells and demonstrates significant inhibitory effects on tumor proliferation. PWT-33597 free base is applicable in research focused on various tumors, including renal cell carcinoma, making it a valuable tool for cancer studies.

    Out of stock

    All 3 sizes
  • PWT-33597
    Cat. No.
    A31599

    PWT-33597

    Synonyms: VDC-597; SN33597

    PWT-33597 is a potent dual inhibitor of PI3Kα and mTOR, effectively disrupting downstream signaling pathways associated with cell growth and survival. This reagent induces apoptosis in tumor cells and demonstrates significant anti-tumor activity. PWT-33597 is a valuable tool for research into various malignancies, including renal cell carcinoma, providing insights into tumor biology and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kα-IN-6
    Cat. No.
    A31628

    PI3Kα-IN-6

    PI3Kα-IN-6 is a selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) pathway. This compound demonstrates significant anticancer activity by promoting the generation of reactive oxygen species (ROS), leading to a decrease in mitochondrial membrane potential (MMP) and subsequently inducing apoptosis in cancer cells. PI3Kα-IN-6 is valuable for research focused on cancer therapeutics and the exploration of PI3K signaling in cell survival and proliferation.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-33
    Cat. No.
    A31664

    PI3K-IN-33

    PI3K-IN-33 is a highly selective inhibitor of phosphoinositide 3-kinases (PI3K), exhibiting IC50 values of 11.73 μM, 6.09 μM, and 11.18 μM for PI3K-α, PI3K-β, and PI3K-δ, respectively. This compound effectively arrests the cell cycle at the G2/M phase and induces apoptosis in various cell types. PI3K-IN-33 is particularly valuable for research applications focused on leukemia and other malignancies driven by aberrant PI3K signaling.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-34
    Cat. No.
    A31865

    PI3K-IN-34

    PI3K-IN-34 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), specifically demonstrating IC50 values of 11.73 μM for PI3K-α, 6.09 μM for PI3K-β, and 11.18 μM for PI3K-δ. This compound effectively induces G2/M cell cycle arrest and promotes apoptotic pathways in targeted cells. PI3K-IN-34 is particularly useful in preclinical studies involving leukemia, providing insights into therapeutic strategies for this malignancy.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kδ/γ-IN-3
    Cat. No.
    A32227

    PI3Kδ/γ-IN-3

    PI3Kδ/γ-IN-3 is a potent dual inhibitor of PI3Kδ and PI3Kγ, with IC50 values of 1 nM and 16 nM, respectively. This compound effectively induces apoptosis in tumor cells, making it a valuable tool for research in B-cell malignancies. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and targeting these pathways in cancer therapy.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes

Items 176-200 of 369

Added to your cart

View Cart Checkout

    Loading...